Igene Biotechnology Inc - Notification that Quarterly Report will be submitted late (NT 10-Q)
15 Novembro 2007 - 8:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
Commission File Number: 000-25349
(Check One): [ ] Form 10-KSB [ ] Form 20-F [ ] Form 11-K [x] Form 10-QSB
[ ] Form N-SAR [ ] Form N-CSR
For Period Ended: September 30, 2007
[ ] Transition Report on Form 10-K and Form 10-KSB
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q and Form 10-QSB
[ ] Transition Report on Form N-SAR
For the Transition Period Ended: ___________________
Nothing in this form shall be construed to imply that the Commission
has verified any information contained herein.
If the notification relates to a portion of the filing checked above,
identify the item(s) to which the notification relates:
PART I
REGISTRANT INFORMATION
Full Name of Registrant: IGENE BIOTECHNOLOGY, INC.
Former Name if Applicable: NA
Address of Principal Executive Office: 9110 RED BRANCH ROAD
City, State and Zip Code: COLUMBIA, MARYLAND 21045-2024
-1-
PART II
RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box if appropriate.)
(a) The reasons described in reasonable detail in Part III of this
form could not be eliminated without unreasonable effort or
expense;
(b) The subject annual report, semi-annual report, transition report
on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or
portion thereof, will be filed on or before the fifteenth calendar
day following the prescribed due date; or the subject quarterly
report or transition report on Form 10-Q, or portion thereof will
[ ] be filed on or before the fifth calendar day following the
prescribed due date; and
(c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
PART III
NARRATIVE
State below in reasonable detail the reasons why the Forms 10-K, 20-F,
11-K, 10-Q, N-SAR, N-CSR, or the transition report or portion thereof, could
not be filed within the prescribed time period.
Additional time will be needed for the Registrant to complete the
preparation of its Quarterly Report on Form 10-QSB (the "Form 10-QSB")
for the quarter ended September 30, 2007. The Registrant was informed
on August 10, 2007 by its independent accountant, J.H. Cohn ("Cohn"), in
connection with its review of Form 10-QSB that they required an
independent valuation of warrants associated with certain debt
obligations of the Registrant. The Registrant will require additional
time to file the Form 10-QSB in order to prepare the warrant valuation
and determine whether any corresponding revaluation of related debt
instruments is material. Prior to completion of this determination,
the Registrant is unable to file and certify the Form 10-QSB.
Based upon its current schedule, the Registrant anticipates that it
will not be in a position to file its Form 10-QSB by the 5th calendar day
following the prescribed due date of the Form 10-QSB.
-2-
PART IV
OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification.
Edward J. Weisberger (410) 997-2599
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d)
of the Securities Exchange Act of 1934 or Section 30 of the
Investment Company Act of 1940 during the preceding 12 months or
for such shorter period that the registrant was required to file
such report(s) been filed? If answer is no, identify report(s).
[x] Yes [ ] No
(3) Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year
will be reflected by the earnings statements to be included in the
subject report or portion thereof?
[x] Yes [ ] No
If so, attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the
reasons why a reasonable estimate of the results cannot be made.
The Registrant is unable to determine whether a significant change
in results of operations for the quarter ending September 30, 2007
will occur until the completion of the independent valuation of the
warrants associated with certain debt obligations of the Registrant.
Until the independent valuation is completed, Registrant has no
reasonable basis to quantify the potential changes, if any, in
results of operations for the period ending September 30, 2007.
Igene Biotechnology, Inc.
(Name of Registrant as Specified in Charter)
Has caused this notification to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: November 15, 2007 By: /s/ EDWARD J. WEISBERGER
_____________________________
EDWARD J. WEISBERGER
Chief Financial Officer
|
-3-
IGENE Biotechnology (CE) (USOTC:IGNE)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
IGENE Biotechnology (CE) (USOTC:IGNE)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024